TY - JOUR
T1 - Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells
T2 - A possible role for exosomal disposal of tumor suppressor miRNAs
AU - Rashed, Mohammed H.
AU - Kanlikilicer, Pinar
AU - Rodriguez-Aguayo, Cristian
AU - Pichler, Martin
AU - Bayraktar, Recep
AU - Bayraktar, Emine
AU - Ivan, Cristina
AU - Filant, Justyna
AU - Silva, Andreia
AU - Aslan, Burcu
AU - Denizli, Merve
AU - Mitra, Rahul
AU - Ozpolat, Bulent
AU - Calin, George A.
AU - Sood, Anil K.
AU - Abd-Ellah, Mohamed F.
AU - Helal, Gouda K.
AU - Berestein, Gabriel Lopez
N1 - Funding Information:
This study was funded by the NIH Common Fund (UH2TR000943), through the Office of Strategic Coordination/Office of the NIH Director and MD Anderson's Cancer Center Support Grant (CCSG) (grant number is CA016672); Ministry of High Education, Cultural affairs and Mission Sector, Joint-Supervision Program, Egypt; and The RNA Center, MD Anderson Cancer Center. We thank Ana Maria Zaske for AFM imaging at IM Bioscope II-UT Core Facility at the Internal Medicine Department, University of Texas Health Science Center at Houston.
PY - 2017
Y1 - 2017
N2 - Exosomes have emerged as important mediators of diverse biological functions including tumor suppression, tumor progression, invasion, immune escape and cell-to-cell communication, through the release of molecules such as mRNAs, miRNAs, and proteins. Here, we identified differentially expressed exosomal miRNAs between normal epithelial ovarian cell line and both resistant and sensitive ovarian cancer (OC) cell lines. We found miR-940 as abundant in exosomes from SKOV3-IP1, HeyA8, and HeyA8-MDR cells. The high expression of miR-940 is associated with better survival in patients with ovarian serous cystadenocarcinoma. Ectopic expression of miR-940 inhibited proliferation, colony formation, invasion, and migration and triggered G0/G1 cell cycle arrest and apoptosis in OC cells. Overexpression of miR-940 also inhibited tumor cell growth in vivo. We showed that proto-oncogene tyrosine-protein kinase (SRC) is directly targeted by miR-940 and that miR-940 inhibited SRC expression at mRNA and protein levels. Following this inhibition, the expression of proteins downstream of SRC, such as FAK, paxillin and Akt was also reduced. Collectively, our results suggest that OC cells secrete the tumor-suppressive miR-940 into the extracellular environment via exosomes, to maintain their invasiveness and tumorigenic phenotype.
AB - Exosomes have emerged as important mediators of diverse biological functions including tumor suppression, tumor progression, invasion, immune escape and cell-to-cell communication, through the release of molecules such as mRNAs, miRNAs, and proteins. Here, we identified differentially expressed exosomal miRNAs between normal epithelial ovarian cell line and both resistant and sensitive ovarian cancer (OC) cell lines. We found miR-940 as abundant in exosomes from SKOV3-IP1, HeyA8, and HeyA8-MDR cells. The high expression of miR-940 is associated with better survival in patients with ovarian serous cystadenocarcinoma. Ectopic expression of miR-940 inhibited proliferation, colony formation, invasion, and migration and triggered G0/G1 cell cycle arrest and apoptosis in OC cells. Overexpression of miR-940 also inhibited tumor cell growth in vivo. We showed that proto-oncogene tyrosine-protein kinase (SRC) is directly targeted by miR-940 and that miR-940 inhibited SRC expression at mRNA and protein levels. Following this inhibition, the expression of proteins downstream of SRC, such as FAK, paxillin and Akt was also reduced. Collectively, our results suggest that OC cells secrete the tumor-suppressive miR-940 into the extracellular environment via exosomes, to maintain their invasiveness and tumorigenic phenotype.
KW - Exosomes
KW - MiR-940
KW - Ovarian cancer
KW - SRC
KW - Tumor suppressive
UR - http://www.scopus.com/inward/record.url?scp=85015782680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015782680&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.15525
DO - 10.18632/oncotarget.15525
M3 - Article
C2 - 28423620
AN - SCOPUS:85015782680
SN - 1949-2553
VL - 8
SP - 20145
EP - 20164
JO - Oncotarget
JF - Oncotarget
IS - 12
ER -